Indomethacin

General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Excreted Unchanged %
30
Half-Life (Normalesrd) Hours
4-12/Unchanged
Plasma Protein Binding %
99
Volume Of Distribution L/Kg
0.12
Dose For Normal Renal Function
25-50 mg tid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Helleberg L. Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981; 6: 245-58. [PMID: 7249487] / Stein G, Kunze M, Zaumseil J, Traeger A. [Pharmacokinetics of indomethacin and indomethacin metabolites administered continuously to patients with healthy or damaged kidneys]. Int J Clin Pharmacol Biopharm. 1977; 15: 470-3. [PMID: 924701]